This study aims to investigate TrxR as a possible therapeutic target by assessing the effectiveness of TrxR inhibitors on CML cells and on overcoming TKI resistance, as well as studying a potential cross talk between bcr-abl and the Trx system. The gene discussed is TXN; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.